Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Login Sign up free
Home Screener Maps Charts News Groups Insider Futures Forex Crypto Portfolio Calendar
Pricing

New feature:   Introducing the Finviz Matrix

Learn More
Market News Market Pulse Stocks News ETF News Crypto News

GT Biopharma, Inc.

Contributing Author

Recent Articles by GT Biopharma, Inc.

Sep-15
GT Biopharma Announces Potential New Indication for GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager, for Multiple Myeloma GTBP -22.61% GlobeNewswire
Sep-11
GT Biopharma to Host Live Company Presentation on the Development of TriKE Platform for Cancer Treatment, September 11, 2026 GTBP +39.32% GlobeNewswire
Aug-14
GT Biopharma Reports Second Quarter 2026 Financial Results GTBP GlobeNewswire
Jun-01
GT Biopharma Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological Initiatives GTBP -7.57% GlobeNewswire
May-15
GT Biopharma Reports First Quarter 2026 Financial Results GTBP -10.25% GlobeNewswire
May-14
GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors GTBP +40.36% GlobeNewswire
Mar-11
GT Biopharma to Participate in the 38th Annual Roth Conference GTBP +5.67% GlobeNewswire
Mar-02
GT Biopharma Reports Full Year 2025 Financial Results GTBP GlobeNewswire
Feb-17
GT Biopharma to Present at the Centurion One Capital 9th Annual Toronto Growth Conference GTBP GlobeNewswire
Feb-03
GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-5550 TriKE, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors Expressing B7-H3 GTBP GlobeNewswire
Jan-15
GT Biopharma Announces IND Submission for GTB-5550 TriKE, a B7-H3-targeted natural killer (NK) cell engager for B7-H3 expressing solid tumor cancers GTBP +10.61% GlobeNewswire
Nov-14
GT Biopharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update GTBP +26.14% GlobeNewswire
Oct-23
GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory (r/r) CD33 Expressing Hematologic Malignancies GTBP +8.99% GlobeNewswire
Oct-08
GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory (r/r) CD33 Expressing Hematologic Malignancies GTBP +43.67% GlobeNewswire
Oct-06
GT Biopharma to Participate in the Centurion One Capital 3rd Annual Bahamas Summit GTBP +10.59% GlobeNewswire
Sep-04
GT Biopharma to Participate in the H.C. Wainwright 27th Annual Global Investment Conference GTBP GlobeNewswire
Aug-14
GT Biopharma Reports Second Quarter 2025 Financial Results GTBP -13.69% GTBP -7.59% GlobeNewswire
Aug-11
GT Biopharma Advances into Cohort 3 of GTB-3650 Phase 1 Trial Following Safety Review of Cohort 2 GTBP GlobeNewswire
Jun-13
GT Biopharma Appoints New Member to its Board of Directors GTBP GlobeNewswire
May-19
GT Biopharma Advances GTB-3650 Phase 1 Trial to Cohort 2 Following Successful Initial Human Dosing and Evidence of Early Immune Activation Signals GTBP GlobeNewswire
May-15
GT Biopharma Appoints New Member to its Board of Directors GTBP GlobeNewswire
May-14
GT Biopharma Appoints New Member to its Board of Directors GTBP GlobeNewswire
Affiliate • Advertise • API and Exports • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)